FOR INVESTORS

SynDaver continues to work toward a long-term plan for a public offering. This effort is supported by the recent breakthroughs made with our new synthetic soft tissue technology, which significantly extends the lifespan of our products and will enable scalable opportunities in international markets and recurring-revenue models such as SynDaver-as-a-service. While we build toward that goal, we are also implementing a share buyback program to provide liquidity options for our early investors. We are currently building funding for this program, which will begin with the retirement of certain bond investments, followed by preferred shares with associated contracts, and then common shares. Buyback offers, if any,  will be made privately, at the company’s discretion and subject to available resources, with the intent to recognize our earliest supporters first.

SynDaver is famous for designing and building synthetic humans. These are made from water, salts and fibers and include all muscles, bones, organs, veins, arteries and other structures found in normal anatomy. The patented library of materials from which they are made mimic living tissues and are used across a wide range of industries, from medical device testing and surgical training, to secondary and college education, as well as consumer product development and weapons and armor testing.

Our customer base is broad, diverse, and global. We sell to Fortune 500 medical device manufacturers, the best hospitals and medical schools in the world and educational institutions with EMT, nursing, anatomy, veterinary medicine, dentistry, engineering, mortuary science, surgical technician, physical therapy and sports science programs. We even sell to middle-school and high-school STEM education and biology programs.

Our industrial customers include the global technology elite: firms such as Alphabet, Apple, Ford, General Electric, Lear, Lululemon, Meta, Microsoft, Nike, Procter and Gamble, Underwriters Laboratories (UL) and many others.

Our government customers include the U.S. Food and Drug Administration, the U.S. Consumer Product Safety Commission, the U.S. State Department, the Health Services of Canada and the UK and every branch of the U.S. military. We also sell to NATO and friendly governments worldwide.

Our media customers include ABC, AMC, CBS, NBC, PBS and The Discovery Channel. Our products have been seen on too many news programs to list, as well as “Shark Tank” (ABC and CNBC), “Grey’s Anatomy” and Good Morning America (ABC), “CSI” (CBS), “Inside Edition” (ABC), “Mythbusters” (Discovery), “Mythbusters 2.0” (Science Channel), “Crossbones” (NBC), “Shipping Wars” (AMC) and “Quest” (PBS).

SynDaver is constantly refining technologies, seeking new markets for existing products and designing new products for emerging applications. We created the SynDaver Synthetic Human (SSH) product line in 2011 with our torso model and followed with our first generation full body in 2012. In 2013 we started designing a line of partial task trainers for nursing and EMS education. In 2017 we launched the SynDaver Surgical Canine for the veterinary medical education community, in 2018 we followed with the SynDaver Advanced Modular Mannequin (SAMM) and in 2019 we launched CopyCat and SynFrog for high school dissection classes.

In 2020 we began offering a silicone version of the SynDaver and in 2024 we launched our new modular canine and Capuchin monkey simulators. In this same year we rolled out an updated formulation for our patented synthetic wet tissues across all product lines. This new system allows our wet tissue products to last essentially forever – opening up the rest of the world as a new market and making the sale of SynDaver as a service possible.

There are currently 19 issued U.S. Patents on our full body of work with many more in process.

SynDaver has been in business since 2004 and we now have thousands of simulators in service across the United States. Our synthetic tissue technology is by far the most advanced in the world. To continue building on our success we will continue to innovate within our existing product lines and develop products for new industries. We are also expanding our sales teams across multiple divisions, adding distributors worldwide and increasing marketing efforts.

Dr. Christopher Sakezles is our Founder, CEO, Chief Technology Officer and Chairman of the Board of Directors for the SynDaver group of companies. He is advised by a group of professionals that changes according to the current needs of the company.

From time to time SynDaver conducts private offerings of its securities to qualified investors. These opportunities are not advertised publicly, and participation is limited to individuals who meet applicable regulatory requirements. Interested parties may request more information by completing the form below; all requests are reviewed privately, and identity verification and nondisclosure procedures apply before any materials are released.

Current investors who need to update their contact information may also use the form below to ensure they receive future correspondence.

Certain statements on this website are forward-looking and based on current expectations. Actual results may differ materially due to various risks and uncertainties. This communication does not constitute an offer to sell or a solicitation to buy any security. Any investment in SynDaver securities is made only through formal offering documents provided to qualified investors.